drugset / Trial / NCT01381055
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
Phase 2/3
Completed
164 enrolled
Paulo Roberto Lima Machado
Conselho Nacional de Desenvolvimento Científico e Tecnológico · collabFederal University of Bahia · collabInstituto Nacional de Ciência e Tecnologia de Doenças Tropicais (INCT-DT) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether pentoxifylline associated to pentavalent antimony has a higher cure rate than pentavalent antimony alone in the treatment of cutaneous leishmaniasis.
Timeline
- Start
- 2012-03
- Primary completion
- 2015-01
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentoxifylline | Small molecule | 400 mg | — |